Aurinia Pharmaceuticals' (AUPH) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) in a research note released on Friday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the biotechnology company’s stock. Separately, StockNews.com assumed coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, August 17th. […]

Related Keywords

United States , ,Aurinia Pharmaceuticals ,Otsuka Pharmaceutical Co Ltd ,Aurinia Pharmaceuticals Inc ,Renaissance Technologies ,Armistice Capital ,Aurinia Pharmaceuticals Trading Down ,News Ratings For Aurinia Pharmaceuticals Daily ,Institutional Trading Of Aurinia Pharmaceuticals ,Bellevue Group ,Free Report ,Moderate Buy ,Pharmaceuticals Trading Down ,Get Free Report ,Street Corp ,Pharmaceuticals Inc ,Aurinia Pharmaceuticals Daily ,Nasdaq Auph ,Auph ,Medical ,Reiterated Rating ,Hc Wainwright ,